Potent and highly selective benzimidazole inhibitors of PI3-kinase delta

Journal of Medicinal Chemistry

Volumn 55, Issue 17, 2012, Pages 7686-7695

  Murray, Jeremy M ^a   Sweeney, Zachary K ^a   Chan, Bryan K ^a   Balazs, Mercedesz ^a   Bradley, Erin ^a   Castanedo, Georgette ^a   Chabot, Christine ^a   Chantry, David ^a   Flagella, Michael ^a   Goldstein, David M ^c   Kondru, Rama ^c   Lesnick, John ^a   Li, Jun ^a   Lucas, Matthew C ^c   Nonomiya, Jim ^a   Pang, Jodie ^a   Price, Stephen ^b   Salphati, Laurent ^a   Safina, Brian ^a   Savy, Pascal P A ^b   Seward, Eileen M ^b   Ultsch, Mark ^a   Sutherlin, Daniel P ^a   more..

^a GENENTECH INC   (United States)

^b Argenta Discovery Ltd   (United Kingdom)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 [2 [2 (1 HYDROXYETHYL) 1H BENZO[D] IMIDAZOL 1 YL] 9 METHYL 6 MORPHOLINO 9H PURIN 8 YL]METHYL]PIPERIDIN 4 YL]PROPAN 2 OL; 2 [1 [5 (2 ETHYLBENZOIMIDAZOL 1 YL) 7 MORPHOLIN 4 YL THIAZOLO[4,5 D]PYRIMIDIN 2 YLMETHYL]PIPERIDIN 4 YL]PROPAN 2 OL; 2 [1 [5 (2 ETHYLBENZOIMIDAZOL 1 YL) 7 MORPHOLIN 4 YL THIAZOLO[5,4 D]PYRIMIDIN 2 YLMETHYL]PIPERIDIN 4 YL]PROPAN 2 OL; 2 [1 [[2 (2 CYCLOPROPYL 1H BENZO[D] IMIDAZOL 1 YL) 9 METHYL 6 MORPHOLINO 9H PURIN 8 YL]METHYL]PIPERIDIN 4 YL]PROPAN 2 ONL; 2 [1 [[2 (2 ETHYL 1H BENZO[D]IMIDAZOL 1 YL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDIN 6 YL]METHYL]PIPERIDIN 4 YL]PROPAN 2 OL; 2 [1 [[2 (2 ETHYL 1H BENZO[D]IMIDAZOL 1 YL) 6 MORPHOLINO 9H PURIN 8 YL]METHYL]PIPERIDIN 4 YL)PROPAN 2 OL; 2 [1 [[2 (2 ETHYL 1H BENZO[D]IMIDAZOL 1 YL) 9 METHYL 6 MORPHOLINO 9H PURIN 8 YL]METHYL)PIPERIDIN 4 YL]PROPAN 2 OL; 2 [1 [[2 (2 ISOPROPYL 1H BENZO[D]IMIDAZOL 1 YL) 9 METHYL 6 MORPHOLINO 9H PURIN 8 YL]METHYL]PIPERIDIN 4 YL]PROPAN 2 OL; 2 [1 [[2 [2 (DIMETHYLAMINO) 1H BENZO[D] IMIDAZOL 1 YL] 9 METHYL 6 MORPHOLINO 9H PURIN 8 YL]METHYL]PIPERIDIN 4 YL]PROPAN 2 OL; 2 [1 [[2-[2 (1 METHOXYETHYL) 1H BENZO[D] IMIDAZOL 1 YL] 9 METHYL 6 MORPHOLINO 9H PURIN 8 YL]METHYL]PIPERIDIN 4 YL]PROPAN 2 OL; 2 [1 [[9 METHYL 6 MORPHOLINO 2 [2 (TETRAHYDROFURAN 2 YL) 1H BENZO[D]IMIDAZOL 1 YL] 9H PURIN 8 YL]METHYL]PIPERIDIN 4 YL]PROPAN 2 OL; 2 [1 [[9 METHYL 6 MORPHOLINO 2 [2 MORPHOLINO 1H BENZO[D]IMIDAZOL 1 YL) 9H PURIN 8 YL]METHYL]PIPERIDIN 4 YL]PROPAN 2 OL; 2 [2 ETHYL BENZOIMIDAZOL 1 YL) 9 METHYL 6 MORPHOLIN 4 YL 8 [(1S,4S) 5 OXETAN 3 YL 2,5 DIAZABICYCLO [2.2.1]HEPT 2 YLMETHYL] 9H PURINE; 2-[4 [2 (2 ETHYL 1H BENZO[D]IMIDAZOL 1 YL) 9 METHYL 6 MORPHOLINO 9H PURIN 8 YL]METHYL]PIPERAZIN 1 YL] 2 METHYLPROPANAMIDE; 4 [1 [[2 (2 ETHYL 1H BENZO[D]IMIDAZOL 1 YL) 9 METHYL 6 MORPHOLINO 9H PURIN 8 YL]METHYL]AZETIDIN 3 YL]MORPHOLINE; 4 [1 [[2 [2 ETHYL 1H BENZO[D]IMIDAZOL 1 YL) 9 METHYL 6 MORPHOLINO 9H PURIN 8 YL]METHYL]AZETIDIN 3 YL]MORPHOLINE; 4 [2 (2 ETHYL 1H BENZO[D]IMIDAZOL-1-YL) 9 METHYL 8 [[4 (METHYLSULFONYL)PIPERAZIN 1 YL]METHYL] 9H PURIN 6 YL]MORPHOLINE; 4 [2 [2 ETHYL 1H BENZO[D]IMIDAZOL 1 YL) 9 METHYL 8 [[4 (METHYLSULFONYL)PIPERAZIN 1 YL]METHYL] 9H PURIN 6 YL]MORPHOLINE; BENZIMIDAZOLE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE DELTA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CHEMICAL INTERACTION; IN VIVO STUDY; NONHUMAN; RAT;

BENZIMIDAZOLES; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84866309700     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300717c     Document Type: Article

References (21)

1. Okkenhaug, K.; Vanhaesebroeck, B. PI3K-signalling in B- and T-cells: insights from gene-targeted mice Biochem. Soc. Trans. 2003, 31, 270-274 (Pubitemid 36241443)
2. Okkenhaug, K.; Vanhaesebroeck, B. PI3K in lymphocyte development, differentiation and activation Nat. Rev. Immunol. 2003, 3, 317-330 (Pubitemid 37328684)
3. Rommel, C.; Camps, M.; Ji, H. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol. 2007, 7, 191-201
4. Thomas, M.; Owen, C. Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea? Curr. Opin. Pharmacol. 2008, 8, 267-274
5. Williams, O.; Hoouseman, B. T.; Kunkel, E. J.; Aizenstein, B.; Hoffman, R.; Knight, Z. A.; Shokat, K. M. Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs Chem. Biol. 2010, 17, 123-34
6. Ihle, N. T.; Powis, G. The biological effects of isoform-specific PI3-kinase inhibition Curr. Opin. Drug Discovery Dev. 2010, 13, 41-49
7. Folkes, A. J.; Ahmadi, K.; Alderton, W. K.; Alix, S.; Baker, S. J.; Box, G.; Chuckowree, I. S.; Clarke, P. A.; Depledge, P.; Eccles, S. A.; Friedman, L. S.; Hayes, A.; Hancox, T. C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A. G.; Pang, J.; Patel, S.; Pergl-Wilson, G. H.; Raynaud, F. I.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M. H.; Valenti, M.; Wallweber, H. J.; Wan, N. C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M. J.; Shuttleworth, S. J. The identification of 2-(1H-indazol-4-yl)-6-(4- methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin -4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer J. Med. Chem. 2008, 51, 5522-5532
8. Marone, R.; Cmiljanovic, V.; Giese, B.; Wymann, M. P. Targeting phosphoinositide 3-kinase: moving towards therapy Biochim. Biophys. Acta 2008, 1784, 159
9. Ihle, N. T.; Powis, G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy Mol. Cancer Ther. 2009, 8, 1-9
10. Raynaud, F. I.; Eccles, S. A.; Patel, S.; Alix, S.; Box, G.; Chuckowree, I.; Folkes, A.; Gowan, S.; De Haven Brandon, A.; Di Stefano, F.; Hayes, A.; Henley, A. T.; Lensun, L.; Pergl-Wilson, G.; Robson, A.; Saghir, N.; Zhyvoloup, A.; McDonald, E.; Sheldrake, P.; Shuttleworth, S.; Valenti, M.; Wan, N. C.; Clarke, P. A.; Workman, P. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 Mol. Cancer Ther. 2009, 8, 1725-1728
11. Sadhu, C.; Masinovsky, B.; Dick, K.; Sowell, C. G.; Staunton, D. E. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement J. Immunol. 2003, 170, 2647-2654 (Pubitemid 36245657)
12. Williams, R.; Berndt, A.; Miller, S.; Hon, W. C.; Zhang, X. Form and flexibility in phosphoinositide 3-kinases Biochem. Soc. Trans. 2009, 27, 615-626
13. Berndt, A.; Miller, S.; Williams, O.; Le, D. D.; Houseman, B. T.; Pacold, J. I.; Gorrec, F.; Hon, W. C.; Liu, Y.; Rommel, C.; Gaillard, P.; Ruckle, T.; Schwarz, M. K.; Shokat, K. M.; Shaw, J. P.; Williams, R. L. The p110delta structure: mechanisms for selectivity and potency of new PI3K inhibitors Nat. Chem. Biol. 2010, 6, 244
14. Zvelebil, M. J.; Waterfield, M. D.; Shuttleworth, S. J. Structural analysis of PI3-kinase isoforms: Identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors. Arch Biochem. Biophys. 2008, 477, 404-410
15. Knight, Z. A.; Gonzalez, B; Feldman, M. E.; Zunder, E. R.; Goldenberg, D. D.; Williams, O.; Loewith, R.; Stokoe, D.; Balla, A.; Toth, B.; Balla, T.; Weiss, W. A.; Williams, R. L.; Shokat, K. M. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling Cell 2006, 125, 733-47
16. Safina, B. S.; Baker, S.; Baumgardner, M.; Blaney, P. M.; Chan, B. K.; Chen, Y.-H.; Cartwright, M. W.; Castanedo, G.; Chabot, C.; Cheguillaume, A. J.; Goldsmith, P.; Goldstein, D. M.; Goyal, B.; Hancox, T.; Handa, R. K.; Iyer, P. S.; Kaur, J.; Kondru, R.; Kenny, J. R.; Krintel, S. L.; Li, J.; Lesnick, J.; Lucas, M. C.; Lewis, C.; Mukadam, S.; Murray, J.; Nadin, A. J.; Nonomiya, J.; Padilla, F.; Palmer, W. S.; Pang, J.; Pegg, N.; Price, S.; Reif, K.; Salphati, L.; Savy, P. A.; Seward, E. M.; Shuttleworth, S.; Sohal, S.; Sweeney, Z. K.; Tay, S.; Tivitmahaisoon, P.; Waszkowycz, B.; Wei, B.; Yue, Q.; Zhang, C.; Sutherlin, D. P. Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition J. Med. Chem. 2012, 55, 5887-5900
17. Sutherlin, D. P.; Sampath, D.; Berry, M.; Castanedo, G.; Chang, Z.; Chuckowree, I.; Dotson, J.; Folkes, A.; Friedman, L.; Goldsmith, R.; Heffron, T.; Lee, L.; Lesnick, J.; Lewis, C.; Mathieu, S.; Nonomiya, J.; Olivero, A.; Pang, J.; Prior, W. W.; Salphati, L.; Sideris, S.; Tian, Q.; Tsui, V.; Wan, N. C.; Wang, S.; Wiesmann, C.; Wong, S.; Zhu, B. Y. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer J. Med. Chem. 2010, 53, 1086-1097
18. Lesnick, J., manuscript in preparation.
19. Peters, J.-U.; Schnider, P.; Mattei, P.; Kansy, M. Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds ChemMedChem 2009, 4, 680-686
20. Avdeef, A; Artursson, P.; Neuhoff, S.; Lazorova, L.; Grasjo, J.; Tavelin, S. Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa(flux) method Eur. J. Pharm. Sci. 2005, 4, 333-349 (Pubitemid 40283516)
21. 2-adrenergic receptor intrinsically modulates the level of IgG1 and IgE produced per B cell J. Immunol. 2000, 165, 680-690 (Pubitemid 30484733)